FINWIRES · TerminalLIVE
FINWIRES

$EDSA

3 stories mentioning EDSA

Every FINWIRES story that references EDSA, newest first.

Sectors

Sector Update: Healthcare Stocks Gain Friday Afternoon

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index increasing 1.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.3%.The iShares Biotechnology ETF (IBB) declined 1%.In corporate news, Teva Pharmaceutical Industries' (TEVA) Teva Pharmaceuticals unit said Friday that a real-world study shows Austedo and Austedo XR tablets improved quality of life for Huntington's disease chorea patients and their caregivers. Teva Pharmaceutical shares were up 0.8%.BioCardia (BCDA) said it has received confirmation from the US Food and Drug Administration that its ongoing heart failure trial may support a premarket approval of the CardiAMP Cell Therapy System for the treatment of ischemic heart failure with reduced ejection fraction. BioCardia shares climbed more than 24%.Edesa Biotech (EDSA) said Friday that new data showed that paridiprubart combined with standard of care treatments was associated with a 32% relative reduction in mortality in patients with acute kidney injury and respiratory distress at 28 days. Edesa Biotech shares dropped 22.4%.

$BCDA$EDSA$TEVA
Wire

Top Midday Stories: Lululemon Down After Fiscal Q1 Results; Amazon Engineers Criticize AI Spending; Hoffman to Exit Microsoft Board

All three major US stock indexes were down late Friday morning following a better-than-expected May jobs report.The May employment report showed nonfarm payrolls rose by 172,000, well above the 88,000 jobs increase expected in a survey compiled by Bloomberg. The unemployment rate remained at 4.3% in May, as expected. The labor force participation rate was also unchanged from 61.8% in April.In company news, Amazon (AMZN) software engineers supported data center restrictions in Seattle while criticizing the technology giant for investing heavily in infrastructure during massive layoffs, CNBC reported, citing public hearings. An Amazon spokesperson toldthat the company does not have any plans to build data centers within the Seattle city limits. Shares were down 0.4% in the recent session.Lululemon Athletica (LULU) shares fell 9.6% after the company reported fiscal Q1 earnings of $1.69 per diluted share, down from $2.60 a year earlier. Analysts polled by FactSet expected $1.68. The company also trimmed guidance for 2026 and now expects EPS of $10.95 to $11.15 on revenue of $11 billion to $11.15 billion.Microsoft (MSFT) said in a regulatory filing that LinkedIn co-founder Reid Hoffman will not stand for re-election to the board of directors at the annual shareholder meeting. Hoffman, a Microsoft board member since 2017, notified the company of his decision on Tuesday. Microsoft's shares were pointing 1.8% lower.Nvidia (NVDA) cleared Samsung Electronics, SK Hynix, and Micron Technology to supply advanced high-bandwidth memory for its HBM4 artificial intelligence accelerators, multiple outlets reported, citing Chief Executive Officer Jensen Huang. Nvidia's shares were down 4.5% in the recent session.Meta Platforms (META) is facing an investigation and a potential fine in Turkey for possible violation of competition rules, the country's Competition Board said. The investigation will determine whether the company violated the country's competition law by integrating its Meta AI service into WhatsApp and preventing third-party general-purpose generative AI chatbots from offering services on WhatsApp. Shares of the company eased 2.3%.Edesa Biotech (EDSA) dropped nearly 24% after the company said that new data showed that paridiprubart combined with standard-of-care treatments was associated with a 32% relative reduction in mortality in patients with acute kidney injury and respiratory distress at 28 days.Price: $252.83, Change: $-0.97, Percent Change: -0.38%

$AMZN$EDSA$LULU$META$MSFT$NVDA
Wire

Edesa Biotech Says Paridiprubart Linked to Lower Risk of Death in Acute Kidney Injury Patients

Edesa Biotech (EDSA) said Friday that new data showed that paridiprubart combined with standard of care treatments was associated with a 32% relative reduction in mortality in patients with acute kidney injury and respiratory distress at 28 days.The company said new analysis of a combined cohort of 101 severely ill patients with acute kidney injury and respiratory distress also showed a 23% relative reduction in major adverse kidney events at 30 days.The company said paridiprubart was well tolerated in the acute kidney injury cohort, with low overall rates of adverse events, serious adverse events, and infections.Edesa said the findings are based on exploratory evaluations but support further evaluation in acute kidney injury patients.Shares of Edesa Biotech were down more than 7% in Friday trading.Price: $6.58, Change: $-0.52, Percent Change: -7.26%

$EDSA